Amnioinfusions to Treat Early Onset Anhydramnios Caused by Renal Anomalies: Background and Rationale for the Renal Anhydramnios Fetal Therapy Trial.
Elizabeth M O'Hare, Angie C Jelin, Jena L Miller...
https://pubmed.ncbi.nlm.nih.gov/30897573/Actively Recruiting
Led by Fetal Care Center, PLLC · Updated on 2024-12-20
35
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are studying fetuses with severe kidney failure that causes very low amniotic fluid, a condition called anhydramnios. This lack of fluid can harm lung development and lead to serious health problems or death shortly after birth. The study aims to find out if repeated amnioinfusions, which add fluid to the amniotic sac, can improve survival chances until dialysis or kidney transplant is possible. This research builds on earlier findings and seeks to improve outcomes for families facing this diagnosis. Participants will be divided into two groups one receiving serial amnioinfusions with routine care, and a control group receiving comfort care without intervention. The amnioinfusions involve injecting sterile fluid into the amniotic cavity using a thin needle guided by ultrasound. The study team will perform these procedures at a specialized fetal care center, adjusting the number of infusions as needed. The trial also includes careful safety monitoring throughout pregnancy and after delivery. During the study, participants will have regular imaging tests like ultrasounds, echocardiograms, and MRIs, along with lab tests to monitor both the fetus and mother. Researchers will track fetal survival to dialysis and transplant, maternal safety up to 30 days after birth, and other pregnancy outcomes such as timing of membrane rupture and delivery. Follow-up will continue until at least two years after birth to assess transplant eligibility and long-term survival.
CONDITIONS
Amnioinfusion for Fetal Renal Failure
K
Kevin P Magee, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fetal Care Center, PLLC
Lead Sponsor
Medical City Children's Hospital
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Serial Amnioinfusion | Comfort Care / Expectant Management |
|---|---|---|
| What it is | Serial infusions of lactated Ringer’s solution (with antibiotic) into the amniotic cavity under ultrasound guidance to restore amniotic fluid. | Pregnancy management without fetal intervention, focusing on comfort-oriented monitoring and delivery planning. |
| Role in the trial | Experimental therapeutic arm receiving serial amnioinfusions. | Control arm receiving no intervention beyond standard expectant management. |
| Primary intent | To mitigate lethal pulmonary hypoplasia by restoring amniotic fluid volume for neonatal survival to dialysis and beyond. | To allow natural disease progression, providing counseling and supportive care without intervention. |
| How it is given or performed | Needle inserted under ultrasound guidance; isotonic fluid infused serially, repeated as needed. | No fetal intervention; routine prenatal monitoring continues until delivery. |
| Evidence status | Preliminary series and nonrandomized studies suggest improved short-term neonatal survival, but long‑term outcomes and consistent benefit remain unclear. | Historically fatal prognosis; natural history without intervention typically results in perinatal or immediate postnatal death. |
| Important risks | Maternal risks include prelabor rupture of membranes, preterm labor, infection, bleeding; neonatal risks include high morbidity, dialysis‑related complications including sepsis and neurologic injury. | Risks include in utero demise or neonatal death due to pulmonary hypoplasia without intervention. |
| Important limitations | Data are limited to small case series and nonrandomized trials; survival beyond infancy is rare and burden of care is high. | No opportunity to improve lung development or postnatal survival exists with non‑intervention. |
| Patient impact | Some neonates survive birth and receive dialysis, providing a chance for longer-term care, though survival beyond infancy remains limited. | No survivors reported; neonatal survival is extremely unlikely without intervention. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - From enrollment until delivery (up to approximately 9 months of pregnancy)
Participants in the experimental group receive serial amnioinfusion procedures to restore amniotic fluid levels in the womb, aiming to improve fetal lung development. Participants in the control group receive comfort care and expectant management without intervention.
Serial amnioinfusion procedures as deemed necessary by the study doctor; routine prenatal visits
Duration - From delivery up to 2 years after birth
Participants and their newborns are monitored to assess maternal safety, fetal survival to dialysis, and survival to kidney transplant eligibility. Monitoring continues through delivery and up to 30 days postpartum for maternal safety, and up to 2 years after delivery for infant survival outcomes.
Follow-up visits for maternal safety up to 30 days postpartum; ongoing assessments for infant survival up to 2 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Elizabeth M O'Hare, Angie C Jelin, Jena L Miller...
https://pubmed.ncbi.nlm.nih.gov/30897573/Jena L Miller, Ahmet A Baschat, Mara Rosner...
https://pubmed.ncbi.nlm.nih.gov/38051327/Fetal Care Center, PLLC
Lead Sponsor
Medical City Children's Hospital
Collaborating Sponsor